According to GOLD, the choice of device should be individualized based on patient ability and preference.1

Do you have patients who want something in-between?

LONHALA MAGNAIR is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

Please see Important Safety Information below and full Prescribing Information and Patient Information for LONHALA MAGNAIR.

DEVICE FEATURES

Administers medication via natural breathing

Administers medication via natural breathing2

Virtually silent administration

Virtually silent administration4

 

Portable and compact design allows it to fit in a discreet carrying bag

Portable and compact design allows it to fit in a discreet carrying bag2*

Closed-system inhalation device for use only with LONHALA (gylcopyrrolate) Inhalation Solution vials(2)

Closed-system inhalation device for use only with LONHALA® (glycopyrrolate) Inhalation Solution vials2

 

Administered in 2-3 minutes with proper assembly and cleaning

Administered in 2-3 minutes with proper assembly and cleaning2,3†

 

 

 
DEVICE FEATURES
 

Device specific challenges - specific breathing technique

Administers medication via natural breathing2

 

Device specific challenges - required setup and maintenance

Virtually silent administration4

 

LONHALA MAGNAIR COPD Device is portable

Portable and compact design allows it to fit in a discreet carrying bag2*

 

Closed-system inhalation device for LONHALA<sup>®</sup> (glycopyrrolate) Inhalation Solution

Closed-system inhalation device for use only with LONHALA® (glycopyrrolate) Inhalation Solution vials2

 

LONHALA MAGNAIR COPD Device has a 2-3 minute administration time

Administered in 2-3 minutes with proper assembly and cleaning2,3†

 

According to GOLD, randomized trials have not identified superiority of one device/formulation.1

GOLD does not endorse any specific treatments.

*Handset is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches. MAGNAIR weighs 10.2 ounces (including batteries).2
Improper cleaning and maintenance may increase administration time.2

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as a rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist. 

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

GOLD=Global Initiative for Chronic Obstructive Lung Disease.


References:
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2018 report. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2018:1-123.
2. LONHALA MAGNAIR [manufacturer’s instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
3. LONHALA MAGNAIR [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
4. Data on file. PARI. Test report: loudness measurement eLete. November 30, 2017.

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.